Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to $927.2 million.

  • ImmunityBio's Total Non-Current Liabilities fell 1489.4% to $927.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $927.2 million, marking a year-over-year decrease of 1489.4%. This contributed to the annual value of $844.9 million for FY2024, which is 1303.77% down from last year.
  • As of Q3 2025, ImmunityBio's Total Non-Current Liabilities stood at $927.2 million, which was down 1489.4% from $904.9 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Total Non-Current Liabilities peaked at $1.1 billion during Q3 2024, and registered a low of $393.9 million during Q1 2021.
  • In the last 5 years, ImmunityBio's Total Non-Current Liabilities had a median value of $844.9 million in 2024 and averaged $799.6 million.
  • In the last 5 years, ImmunityBio's Total Non-Current Liabilities skyrocketed by 11025.27% in 2021 and then plummeted by 1592.2% in 2025.
  • ImmunityBio's Total Non-Current Liabilities (Quarter) stood at $712.4 million in 2021, then rose by 10.97% to $790.5 million in 2022, then rose by 22.91% to $971.6 million in 2023, then dropped by 13.04% to $844.9 million in 2024, then increased by 9.74% to $927.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $927.2 million for Q3 2025, versus $904.9 million for Q2 2025 and $873.7 million for Q1 2025.